CHOSA
INTELLIGENT ONCOLOGY

Information on Warrant Exercise CHOSA Oncology AB TO 2

REFERENCE TO SIMPLIFIED INFORMATION DOCUMENT

The Company has prepared and published a simplified information document in accordance with Spotlight Stock Market's regulations ("Simplified Information Document"). The Simplified Information Document is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended ("Prospectus Regulation"). Please review the Simplified Information Document relating to the rights issue in order to understand the potential risks associated with an investment in the Company before any investment decision is made.

The Simplified Information Document is available on the Company's website (www.chosaoncology.com).

CHOSA ONCOLOGY AB

Business Update

In June 2025, CHOSA completed a unit issue consisting of shares and warrants (TO2), raising just over SEK 5 million. If all outstanding TO2 warrants are exercised, the Company will receive an additional approximately SEK 6.2 million before issue costs.

A Significant Market Opportunity

Platinum-based chemotherapy remains one of the foundations of modern cancer treatment. Cisplatin and carboplatin are approved across 16 cancer indications and are standard therapies in major cancers including lung, bladder and breast cancer. In lung cancer alone, more than one million patients receive platinum-based chemotherapy each year, often in combination with PD-(L)1 immunotherapy.

Despite their widespread use, there is currently no established biomarker to identify which patients are most likely to benefit from platinum treatment. As a result, many patients receive chemotherapy with limited clinical benefit while being exposed to unnecessary toxicity and valuable treatment time may be lost before alternative therapies are introduced.

A First-in-Class Precision Medicine Solution

CHOSA holds the global rights to a patented gene-expression biomarker, Platin-DRP®, designed to predict which patients are most likely to benefit from treatment with cisplatin and carboplatin.

Developed over more than a decade, Platin-DRP® is the first clinically validated predictive biomarker for platinum chemotherapy. By enabling more precise patient selection, the test has the potential to improve treatment outcomes while reducing unnecessary toxicity in patients unlikely to respond.

Strong and Growing Clinical Evidence

Platin-DRP® has been validated in multiple independent clinical studies in lung and breast cancer with results published in leading oncology journals, including Annals of Oncology and Journal of Clinical Oncology. The clinical evidence was further strengthened in 2026 with statistically significant data presented at ELCC from the Phase III SPLENDOUR lung cancer trial and at ASCO from the I-SPY2 breast cancer study.

In the SPLENDOUR trial, patients with high Platin-DRP® scores achieved a median overall survival of 16.9 months compared with only 5.5 months for patients with low scores - an improvement of almost one year. These findings demonstrate the biomarker's ability to identify the patients who derive the greatest benefit from platinum-based chemotherapy.

Platin-DRP® has the potential to:

- Improve treatment outcomes through better patient selection.
- Reduce unnecessary toxicity by avoiding ineffective chemotherapy.
- Increase the value of existing platinum-based treatment regimens without requiring new drugs.
- Support more efficient use of healthcare resources by directing treatment to the patients most likely to benefit.

A Differentiation Opportunity for Immuno-Oncology

Platinum chemotherapy forms the backbone of treatment for several of the world's highest-selling PD-(L)1 immunotherapies. As more than 11 PD-(L)1 therapies are already approved and over 20 additional candidates are in clinical development, differentiation is becoming increasingly important. This trend will accelerate as major patents begin to expire from 2028 and biosimilar competition intensifies.

By enabling precision selection of patients for platinum-based combination therapy, Platin-DRP® offers pharmaceutical companies a compelling opportunity to improve clinical outcomes, strengthen product differentiation and potentially expand market share.

CHOSA is actively engaged in discussions with both established pharmaceutical and diagnostic companies regarding strategic collaborations and commercialization of Platin-DRP®.

MILESTONES SINCE ISSUE 2025

Lung cancer study readout – Q2 2025

Positive data from the ETOP/EORTC collaboration (SPLENDOUR Phase III) showed that Platin-DRP® predicts survival benefit from cisplatin and carboplatin treatment in advanced non-small cell lung cancer.

Initiation of new research group collaborations – Q3 2025

New research group collaborations initiated as planned.

Expansion of DRP application to additional cancer indications – Q4 2025

In December 2025, Platin-DRP® was validated on the NanoString platform, doubling the addressable market.

Readout from lung cancer combination therapy study – Q1 2026

Presented at the European Lung Cancer Congress in Copenhagen in March 2026: Platin-DRP® predicts statistically significant improvement in overall survival (OS) and progression-free survival (PFS) in advanced non-small cell lung cancer.

Partnership with Mount Sinai, New York – Q2 2026

New partnership established to test the biomarker in studies combining platinum with immunotherapy in lung cancer.

ASCO 2026 – Q2 2026

CHOSA and AIDA Oncology presented data at ASCO 2026 in Chicago: up to 78% pCR rate (pathological complete response) in breast cancer when Platin-DRP® was combined with AIDA's taxane predictor Oncotect®, based on the I-SPY2 study.

INVESTMENT HIGHLIGHTS

✓

The only test that predicts who responds to platinum chemotherapy

Today, clinicians cannot determine in advance which patients will actually benefit from cisplatin and carboplatin. CHOSA's Platin-DRP® is the only available test that can provide that answer, protected by global patents.

✓

Approved by the FDA and EMA

Regulatory authorities in both the United States and Europe have approved Platin-DRP® for selecting patients for clinical trials - an uncommon regulatory validation for a company at this stage.

✓

Major clinical progress – limited capital requirement

CHOSA runs no costly proprietary clinical programmes. Instead, the Company connects its test to ongoing studies, generating clinical evidence at a fraction of the cost of a traditional pharmaceutical company.

✓

Large and growing market – with increasing pressure for differentiation

There are currently 11 approved PD-(L)1 drugs with similar efficacy. As patents begin expiring in 2028, pharmaceutical companies must find ways to stand out. CHOSA's test offers exactly that, in a market expected to exceed USD 150 billion by 2032.

✓

Strong collaboration partners

CHOSA works with leading research institutions: ETOP/EORTC in Europe and Mount Sinai in New York. The validation on the NanoString platform (Dec 2025) doubles the number of hospitals able to use the test.

✓

Proven in over a decade of clinical research

Platin-DRP® is supported by at least 9 published studies and abstracts across lung cancer, breast cancer, and multiple myeloma. Most recent results: Phase III SPLENDOUR (ELCC 2026) in lung cancer and 78% complete tumour response in breast cancer (ASCO 2026). Validated and published in leading journals including Annals of Oncology and Journal of Clinical Oncology.

EXERCISE OF WARRANTS

Terms	One (1) warrant of series TO2 entitles the holder to subscribe for one (1) newly issued share in CHOSA Oncology AB (publ).
Subscription price	SEK 0.78 per share
Number of warrants	7,951,740 warrants of series TO2
Subscription period	1 July – 14 July 2026
Last day of trading in TO2	10 July 2026
Payment	At time of exercise

Exercise of Nominee-Registered Warrants (e.g. Avanza/Nordnet)

Holders of warrants with nominee-registered holdings (securities custody accounts, investment savings accounts (ISK) or endowment insurance policies) must notify the exercise of their warrants by contacting their respective nominee and following the nominee's instructions regarding subscription and payment. This should be done well in advance of 14 July 2026, as different nominees have different processing times.

Exercise of Directly Registered Warrants

Holders of warrants with directly registered holdings (VP accounts) must notify the exercise by completing and submitting a subscription form so that it is received by the issuing agent Nordic Issuing no later than 14 July 2026. The subscription form is available on the websites of CHOSA Oncology AB and Nordic Issuing (www.chosaoncology.com, www.nordic-issuing.se).

Payment must be received by Nordic Issuing no later than 14 July 2026.

Important notice: Subscription and payment for the new shares should be made well in advance of 14 July 2026, as different nominees have different processing times. This may result in an earlier last day of subscription with your nominee. Warrants that are not exercised by 14 July 2026 at the latest, or sold by 10 July 2026 at the latest, will expire without value.